Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52 Efficacy in a third...
AstraZeneca and Daiichi Sankyo’s ENHERTU is the first and only HER2-directed medicine to improve progression-free survival over global standard of...
First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO...
September S&P 500 E-Mini futures (ESU26) are up +0.57%, and September Nasdaq 100 E-Mini futures (NQU26) are up +0.47% this morning, pointing to a higher open on Wall Street as oil prices sank after U.S....
Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting CLARITY-Gastric01...
Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030
September Nasdaq 100 E-Mini futures (NQU26) are up +0.46% this morning, led by advances in chip and other AI-linked shares, while investors kept a close eye on developments in the Middle East.
Five-year, multimillion-dollar partnership kicks off with cancer screening and early detection education initiative in 75 communities
Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19% ...
Switching to camizestrant led to a 99% median reduction in total ctDNA vs. a 64% increase for patients who remained on standard of care 51% of patients...
